Like rock posters, album art, and comix, blotter art played a crucial role in shaping the counterculture experience. The post...
The company made $364,500 in licensing revenues. The post Psychedelic Research Firm Filament Health Grows Pipeline in 2022 appeared first on Green Market...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, released its fourth quarter...
Psychedelic Facilitators vs. Psychedelic Therapists Psychedelic therapists and psychedelic facilitators are not the same, though they both have important...
The article Chrisitian Angermayer Shows Faith in Atai, Buys Another 1.2 M Shares was originally published on Microdose. On March 29th, Christian Angermayer,...
The company's debts totaled C$136.5 million by the end of 2022. The post Mydecine Cuts Down on Annual Cash Burn Despite Mounting Debt appeared first on...
The article News You Might Have Missed: April 3rd, 2023 was originally published on Microdose. Welcome to the News You Might Have Missed, a weekly roundup...
The munKNEE Psychedelic Drug Stocks Index was DOWN 3.4% in March but is still UP 1.2% YTD and the average price targets of the above stocks represent...
The commission will be investigating the risks and benefits associated with MDMA-assisted therapy The post Dutch government establishes MDMA research...
A common anesthesia drug could be beneficial in reducing pressure inside the skull of children with traumatic brain injuries (TBI), according to a study...
Initiatives towards psychedelic policy reform are taking place in Europe, from a conference on psychedelic-assisted therapies at the European Parliament...
Compared to other psychedelic conferences, ECNP was a dose of European realism - from the anticipated effect sizes of psychedelic trials to the cut and...
If you own or operate one of the estimated 1,500 ketamine clinics in the U.S. that provides cutting-edge Ketamine-Assisted Psychotherapy (KAP) to treat...
The article Oregon Issues First Psilocybin Licenses. Now What? was originally published on Microdose. This article originally appeared on the Harris Bricken...
The study is expected to cost C$2.7 million and will run for three months. The post Cantheon Provides Funding to Albert Labs for Psilocybin Drug Development...
On the season three premiere of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Joël Brierre. Joel Brierre is the Founder and CEO of...